Published in CNS Drugs on January 01, 2001
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry (2014) 2.57
Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry (2009) 1.91
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract (2005) 1.30
A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities. Am J Addict (2010) 1.04
Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull (2008) 1.02
Treatment of tobacco dependence in people with mental health and addictive disorders. Curr Psychiatry Rep (2012) 0.99
A comprehensive model for mental health tobacco recovery in new jersey. Adm Policy Ment Health (2011) 0.99
Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci (2003) 0.93
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
Lactational state modifies alcohol pharmacokinetics in women. Alcohol Clin Exp Res (2007) 0.87
Smoking behaviour and mental health disorders--mutual influences and implications for therapy. Int J Environ Res Public Health (2013) 0.85
Cigarette smoking modulates medication-associated deficits in a monetary reward task in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2012) 0.84
Smoking reduction for persons with mental illnesses: 6-month results from community-based interventions. Community Ment Health J (2011) 0.81
Smoking cessation in patients with psychiatric disorders. Prim Care Companion J Clin Psychiatry (2008) 0.80
Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report. J Med Case Rep (2016) 0.79
The effect of nicotine dependence on psychopathology in patients with schizophrenia. Biomed Res Int (2015) 0.77
A Review of Impact of Tobacco Use on Patients with Co-occurring Psychiatric Disorders. Tob Use Insights (2016) 0.77
Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial. Nicotine Tob Res (2016) 0.77
Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol (2007) 0.76
Tobacco use among individuals with intellectual or developmental disabilities: a brief review. Intellect Dev Disabil (2009) 0.75
Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats. J Thorac Dis (2015) 0.75
Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci (2016) 0.75
Smoking Use and Cessation Among People with Serious Mental Illness. Yale J Biol Med (2015) 0.75
Nicotine dependence and psychosis in Bipolar disorder and Schizoaffective disorder, Bipolar type. Am J Med Genet B Neuropsychiatr Genet (2015) 0.75
Does the number of previous mood episodes moderate the relationship between alcohol use, smoking and mood in bipolar outpatients? BMC Psychiatry (2017) 0.75
Smoking, psychiatric illness and the brain. J Psychiatry Neurosci (2017) 0.75
A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis. Hosp Pharm (2016) 0.75
Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit (2014) 0.75
Investigating causality in associations between smoking initiation and schizophrenia using Mendelian randomization. Sci Rep (2017) 0.75
Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs (2017) 0.75
Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study. J Clin Psychopharmacol (1991) 1.39
Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry (1998) 1.12
Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm (1992) 1.08
Major depression in women: a review of the literature. J Am Pharm Assoc (Wash) (2000) 1.01
Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry (1999) 0.95
Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet (1985) 0.94
Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol (2001) 0.89
Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther (1991) 0.89
EEG-based, neural-net predictive classification of Alzheimer's disease versus control subjects is augmented by non-linear EEG measures. Electroencephalogr Clin Neurophysiol (1994) 0.85
Plasma haloperidol and reduced haloperidol concentrations in a geriatric population. Neuropsychobiology (1996) 0.85
Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit (1996) 0.84
Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry (2000) 0.84
Butorphanol as a dental premedication in the mentally retarded. Oral Surg Oral Med Oral Pathol (1987) 0.83
Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol (1991) 0.83
Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J Psychopharmacol (2000) 0.82
Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. Drugs Aging (2000) 0.81
Psychiatric pharmacy practice specialty certification process. Am J Health Syst Pharm (1998) 0.80
Pharmacokinetics of haloperidol. Clin Pharmacokinet (1989) 0.80
Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry (1984) 0.80
Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry (2001) 0.79
Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry (1985) 0.79
Intra- and interethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol (1995) 0.79
Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol (1984) 0.79
In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology (Berl) (1999) 0.78
Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) (1986) 0.78
Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol (1994) 0.78
Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion. Am J Health Syst Pharm (2000) 0.77
Flash P2 delay in primary degenerative dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.77
Increased lithium serum and red blood cell concentrations during ketorolac coadministration. J Clin Psychopharmacol (1998) 0.77
Clozapine dosages and plasma drug concentrations. J Formos Med Assoc (1997) 0.77
Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology (Berl) (1992) 0.77
Therapeutic frontiers in Alzheimer's disease. Pharmacotherapy (1992) 0.77
Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. J Clin Pharmacol (1996) 0.76
Effect of thioridazine on gap junction intercellular communication in connexin 43-expressing cells. Cell Biol Toxicol (2006) 0.76
Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res (1997) 0.76
Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metabol Drug Interact (2001) 0.76
Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol (1985) 0.75
Nonphysician prescribers. J Clin Psychiatry (1994) 0.75
Comment: significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother (1999) 0.75
Differences in haloperidol epidemiologic pharmacokinetic studies. J Clin Psychopharmacol (2001) 0.75
Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry (1997) 0.75
Alternative drug therapies for mania: a literature review. Drug Intell Clin Pharm (1984) 0.75
Elevated plasma clozapine concentrations after phenobarbital discontinuation. J Clin Psychiatry (1998) 0.75
Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr (1993) 0.75
Use of carbamazepine in psychiatric disorders. Clin Pharm (1985) 0.75
Respiratory dyskinesia. Psychosomatics (1982) 0.75
Transitional polytherapy, liver enzymes, and valproic acid hepatotoxicity. Neurology (1987) 0.75
Carbamazepine for patients with affective target symptoms. Drug Intell Clin Pharm (1984) 0.75
Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr Res (1993) 0.75
Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol. Eur Neuropsychopharmacol (1994) 0.75
Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. Psychiatry Res (1997) 0.75
Clinical implications of the neuroleptic-opioid interaction. Drug Intell Clin Pharm (1986) 0.75
Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients. Biol Psychiatry (1993) 0.75
A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry (1996) 0.75
Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy (1997) 0.75
Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry (1986) 0.75
Interaction of dietary pudding with phenytoin. Pediatrics (1986) 0.75
Lithium prophylaxis of tricyclic-antidepressant-induced mania in bipolar patients. Am J Psychiatry (1982) 0.75
Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biol Psychiatry (1989) 0.75
Disposition of remoxipride in Chinese schizophrenic patients. Int J Clin Pharmacol Ther (1996) 0.75
Clinical pharmacists' impact on prescribing in an acute adult psychiatric facility. Drug Intell Clin Pharm (1984) 0.75
Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics. Prog Neuropsychopharmacol Biol Psychiatry (1993) 0.75
Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. Clin Pharmacokinet (1995) 0.75
Disposition of olanzapine in Chinese schizophrenic patients. Int J Clin Pharmacol Ther (2000) 0.75
Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients. Psychiatry Res (1995) 0.75
Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. Neuropsychopharmacology (1992) 0.75
Effect of influenza vaccine on serum anticonvulsant concentrations. Clin Pharm (1986) 0.75
Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J Formos Med Assoc (1991) 0.75